531210.BO Stock Analysis
53
Avoid
Based on Eyestock quantitative analysis, 531210.BO`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly overvalued
Colinz Laboratories Ltd. engages in the manufacture of pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, injectable, ointments, and creams. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2004-01-13. The firm is engaged in the manufacturing and marketing various allopathic and ayurvedic pharmaceutical formulations in the dosage forms of tablets, capsules, liquid orals and ointments, among others. The company provides physicians with products in the treatment of hypertension, cholesterol, diabetes, piles, pyrexia and malaria. The company provides gynecologists with specialized products in the treatments of morning sickness, infertility, intrauterine growth restriction (IUGR) and maintenance of pregnancy. The company also offers other products, such as hematinic, antispasmodics, anti-inflammatory/anti-allergic tablets, capsules gel and medicated shampoo. The firm markets its products in the states of Maharashtra, Karnataka, Andhra Pradesh, Gujarat, Rajasthan, Madhya Pradesh, Chhattisgarh and West Bengal through its own marketing staff.